This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction

We have previously demonstrated that chondroitin sulfate glycosaminoglycans (CS-GAGs) on breast cancer cells function as P-selectin ligands. This study was performed to identify the carrier proteoglycan (PG) and the sulfotransferase gene involved in synthesis of the surface P-selectin-reactive CS-GAGs in human breast cancer cells with high metastatic capacity, as well as to determine a direct role for CS-GAGs in metastatic spread.

Methods

Quantitative real-time PCR (qRT-PCR) and flow cytometry assays were used to detect the expression of genes involved in the sulfation and presentation of chondroitin in several human breast cancer cell lines. Transient transfection of the human breast cancer cell line MDA-MB-231 with the siRNAs for carbohydrate (chondroitin 4) sulfotransferase-11 (CHST11) and chondroitin sulfate proteoglycan 4 (CSPG4 ) was used to investigate the involvement of these genes in expression of surface P-selectin ligands. The expression of CSPG4 and CHST11 in 15 primary invasive breast cancer clinical specimens was assessed by qRT-PCR. The role of CS-GAGs in metastasis was tested using the 4T1 murine mammary cell line (10 mice per group).

Results

The CHST11 gene was highly expressed in aggressive breast cancer cells but significantly less so in less aggressive breast cancer cell lines. A positive correlation was observed between the expression levels of CHST11 and P-selectin binding to cells (P < 0.0001). Blocking the expression of CHST11 with siRNA inhibited CS-A expression and P-selectin binding to MDA-MB-231 cells. The carrier proteoglycan CSPG4 was highly expressed on the aggressive breast cancer cell lines and contributed to the P-selectin binding and CS-A expression. In addition, CSPG4 and CHST11 were over-expressed in tumor-containing clinical tissue specimens compared with normal tissues. Enzymatic removal of tumor-cell surface CS-GAGs significantly inhibited lung colonization of the 4T1 murine mammary cell line (P = 0.0002).

Conclusions

Cell surface P-selectin binding depends on CHST11 gene expression. CSPG4 serves as a P-selectin ligand through its CS chain and participates in P-selectin binding to the highly metastatic breast cancer cells. Removal of CS-GAGs greatly reduces metastatic lung colonization by 4T1 cells. The data strongly indicate that CS-GAGs and their biosynthetic pathways are promising targets for the development of anti-metastatic therapies.

Introduction

Tumor-associated glycans play a significant role in promoting aggressive and metastatic behavior of malignant cells [1-5], participating in cell-cell and cell-extracellular matrix interactions that promote tumor cell adhesion and migration. Among glycans that play a critical role in stromal tumor cell interactions are glycosaminoglycans (GAGs) attached to proteoglycans (PGs). Altered production levels of PGs and structural changes in their GAGs are reported in many neoplastic tissues [6-10]. GAGs are polysaccharide chains covalently attached to protein cores that together comprise PGs [6,11] and based on the prevalence of GAG chains, chondroitin sulfate (CS)/dermatan sulfate (DS) PGs (CS/DS-PGs), heparan sulfate PGs and keratan sulfate PGs have been described [12]. Increased production of CS/DS-GAGs is found in transformed fibroblasts and mammary carcinoma cells [8,13,14] and it has been shown that these polysaccharides contribute to fibrosarcoma cell proliferation, adhesion and migration [15].

Several studies have disclosed the critical involvement of P-selectin in the facilitation of blood borne metastases [16-18]. P-selectin/ligand interaction often requires sialylated and fucosylated carbohydrate such as sialyl Lewis X and sialyl Lewis A [19]; however, P-selectin also binds to heparan sulfate, certain sulfated glycolipids and CS/DS-GAGs [20-23]. In previous studies we found that CS/DS-GAGs are expressed on the cell surface of murine and human breast cancer cell lines with high metastatic capacity and that they play a major role in P-selectin binding and P-selectin-mediated adhesion of cancer cells to platelets and endothelial cells [24]. However, variation in the abundance and function of CS/DS relative to tumor cell phenotypic properties and P-selectin binding are not well defined. It is likely that P-selectin binding to tumor cells and the functional consequences of such binding are dependent on which sulfotransferases define the relevant CS/DS and which core proteins carry the CS polysaccharide.

CS/DS expression is controlled by many enzymes in a complex biosynthetic pathway and this leads to considerable variation in structure and function. The chondroitin backbone of CS/DS-GAGs consists of repetitive disaccharide units containing D-glucuronic acid (GlcA) and N-acetyl-D-galactosamine (GalNAc) residues, or varying proportions of L-iduronic acid (IdoA) in place of GlcA [25,26]. Major structural variability of the CS/DS chains is due to the sulfation positions in repeating disaccharide units by the site-specific activities of sulfotransferases that produce the variants CS-A, CS-B (dermatan sulfate, DS), CS-C, CS-D and CS-E [26,27]. CHST3, CHST7, CHST11, CHST12, CHST13, CHST14 and CHST15 are the enzymes that sulfate the GalNAc residues of chondroitin polymers. The expression levels of these enzymes are hypothesized to affect the production of P-selectin ligands. CHST11 and CHST13 share specificity, as they mediate 4-O sulfation of chondroitin [28-30]. CHST12 and CHST14 mediate mostly 4-O sulfation of DS units [30,31]. CHST3 and CHST7 share specificity for 6-O sulfation of chondroitin [32,33]. CHST15 transfers sulfate to the carbon-6 of an already 4-O sulfated GalNAc residue producing oversulfated CS-E [34]. The relationship between the relative expression of these sulfotransferases with the expression of P-selectin-reactive CS/DS-GAGs has not been reported and is addressed in this paper.

The variation, abundance and function of CS/DS-GAGs are also affected by the expression of the PG core protein presenting them. Syndecan-1 (SDC-1), syndecan-4 (SDC-4), neuropilin-1 (NRP-1) and CSPG4 are considered major pro-malignancy membrane proteins capable of carrying CS chains [35-39]. Among these PGs, CSPG4 exclusively carries CS chains [40,41]. CSPG4 is a human homolog of Rat NG2, which is also known as High Molecular Weight Melanoma Associated Antigen and Melanoma Chondroitin Sulfate Proteoglycan [40,42,43]. This tumor-associated cell surface PG potentiates cell motility and promotes invasiveness and the metastatic potential of tumor cells in melanoma [44-46]. CSPG4 is also linked to cancer stem cells via signaling mechanisms [39,45]. Therefore, studying whether this PG interacts directly with P-selectin is of particular interest.

The expression of CSPG4 in breast cancer has been reported very recently [39]. Depending on its relative expression levels, this PG might be a major core protein presenting CS-GAGs on an aggressive subset of tumor cells, interacting with P-selectin. In the current study we investigated whether CSPG4, via its CS/DS chain can serve as a P-selectin ligand and whether expression of specific chondroitin sulfotransferases contributes to P-selectin interaction with cells. We further examined the involvement of CS-GAG chains in lung colonization by the 4T1 mammary cell line with and without enzymatic removal of CS-GAGs in a murine experimental metastasis model. Our data show for the first time that P-selectin can bind to tumor cells via CSPG4 and that CHST11 expression is linked to P-selectin-reactive cell surface CS/DS-GAGs. The results directly link CS/DS-GAGs to the metastatic spread of breast cancer. These findings have significant implications for understanding mechanisms of breast cancer metastasis, paving the way towards developing alternative strategies to treat and prevent metastasis.

De-identified frozen specimens from 15 female breast cancer patients diagnosed with invasive ductal carcinoma were provided by the University of Arkansas for Medical Sciences (UAMS) Tissue Procurement Facility. Specimens were matched for each donor to have both tumor-free and tumor-containing breast tissues. According to the policy of the Tissue Procurement Facility, patients signed consent forms to donate excess specimen tissue and to allow use of related pathological data for research purposes, which were approved by the UAMS Institutional Review Board. For this study, an active human tissue use protocol approved by the UAMS Institutional Review Board was used. In this protocol, informed consent was waived due to the use of de-identified specimens with no link to patient identifiers.

Total RNA isolation and qRT-PCR

Total RNA was isolated from cultured cells and tumor tissues using TRIzol reagent, following the manufacturer's instructions. The quantity and quality of the isolated RNA was determined by Agilent 2100 Bioanalyzer (Palo Alto, CA, USA). One μg of total RNA was reverse-transcribed using random-hexamer primers with TaqMan Reverse Transcription Reagents (Applied Biosystems). Reverse-transcribed RNA was amplified with SYBR Green PCR Master Mix (Applied Biosystems) plus 0.3 μM of gene-specific upstream and downstream primers during 40 cycles on an Applied Biosystems 7500 Fast Realtime cycler. Data were analyzed by absolute and relative quantification. In absolute quantification, data were expressed in relation to 18S RNA, where the standard curves were generated using pooled RNA from the samples assayed. In relative quantification, the 2 (-Delta Delta C(T)) method was used to assess the target transcript in a treatment group relative to that of an untreated control group using expression of an internal control (reference gene) to normalize data [51]. Expression of GAPDH and β-actin was used as internal control. Each cycle consisted of denaturation at 95°C for 15 s, and annealing and extension at 60°C for 60 s. The primer sequences are shown in Table ​Table11.

Flow cytometry

Binding of the recombinant human P-selectin/Fc molecule, anti-CS-A (2H6) and anti-CSPG4 (225.28) mAb to cells was determined using flow cytometry as previously described [24]. Briefly, cells were incubated with mAb or P-selectin/Fc, washed and stained with FITC-conjugated anti-mouse IgM or anti-human IgG prior to binding detection by flow cytometry. R-phycoerythrin-conjugated polyclonal goat anti-mouse F(ab')2 was used as secondary for detection of anti-CSPG4 binding.

Switching off gene expression with siRNA

Three pre-designed siRNA sequences for CHST11 (Ambion) were used (Table ​(Table1).1). NG2 siRNA (sc-40771) from Santa Cruz Biotechnology, Inc. was used for inhibition of CSPG4. These sequences were transfected into cells growing in tissue culture using the siPORT™ NeoFX™ Transfection Agent, and mRNA levels were determined 48 hours later by real-time PCR. Expression of GAPDH was used as reference control. Reactivity of anti-CS-A mAb 2H6 and human recombinant P-selectin was assessed 144 hours after siRNA transfection. Transfection with GAPDH siRNA (Ambion) was used as control.

Mice and tumor models

BALB/c female mice (six to eight weeks old) were from Harlan Laboratories (Indianapolis, IN, USA). We used 4T1 cells in an experimental metastasis model [24]. Cells were treated with chondroitinase ABC in HBSS buffer with protease inhibitors [24], or with the buffer and protease inhibitor alone (no chondroitinase ABC treatment) before inoculation through the tail vein. Each mouse (10 mice per group) received 2 × 104 4T1 cells. Mice were sacrificed 25 days after tumor cell injection and lungs were harvested to determine clonogenic cells by growing cells in medium containing 6-thioguanine [52]. Animal studies have been reviewed and approved by the Institutional Care and Use Committee of UAMS.

Statistical analysis

For comparison of gene expression between cell lines, the raw amount for each mRNA was normalized to the control mRNA (18S) amount and then log transformed, and analyzed via one-way ANOVA with Tukey's post-hoc procedure. For the tissue comparisons of gene expression in patient samples, the tumor/normal expression ratios for each patient were log-transformed and subjected to one-sample t-tests. For siRNA effects on relative mRNA levels mean fluorescence intensities of antibody binding were log transformed and analyzed via ANOVA and Tukey's post-hoc procedure. Associations between mean fluorescence intensities of P-selectin binding and quantities of sulfotransferase transcripts were characterized using Pearson correlation tests on log-transformed data. In order to check the validity of assumptions for running Pearson's test, Spearman correlation analysis was also performed and when correlation coefficients were similar, assumptions were considered valid. For clonogenic assay comparisons, the number of clonogenic lung metastases was analyzed between groups by the Wilcoxon rank-sum test.

Results

We have shown that CS/DS-GAGs expressed on the cell surface of MDA-MB-231 and MDA-MET human breast cancer cells function as P-selectin ligand and that exogenous CS-E efficiently inhibits P-selectin binding to cells [24]. Among the major sulfotransferases able to sulfate the GlaNAC residue of the chondroitin disaccharide, CHST11, CHST12, and CHST13 are chondroitin 4-sulfotransferases, able to catalyze sulfation of chondroitin on the carbon-4 position of GalNAc sugars in disaccharide GAG units, producing primarily CS-A units (GlcAβ1-3GalNAc (4-SO4)) [28-30]. CHST14, dermatan 4-sulfotransferase 1 (D4ST-1), is specific for 4-O sulfation of the GalNAc in CS-B (DS) units after dermatan sulfate epimerase activity and its specificity can be shared by CHST12 [30,31]. CHST3 and CHST7 are chondroitin 6-sulfotransferases that transfer sulfate to carbon-6 position of GalNAc, competing with 4-sulfotransferases for the same substrate, producing primarily CS-C units (GlcAβ1-3GalNAc (6-SO4)) [32,33]. CHST15, GalNAc 4-sulfate 6-O-sulfotransferase (GalNAc4S-6ST), transfers sulfate to the carbon-6 of a 4-sulfated GalNAc, producing CS-E (GlcAβ1-3GalNAc (4-, 6-SO4)) [34].

Quantitative real-time PCR was used to monitor the expression levels of these genes in several human breast cancer cell lines differing in their cancer phenotype. The human breast cancer cell lines MCF7, MDA-MB-468, MDA-MB-231, and MDA-MET represent increasing aggressiveness and metastatic capacity (MCF7 < MDA-MB-468 < MDA-MB-231 = MDA-MET). While expression of all genes was detected in these breast cancer cells, CHST13 expression was observed to be very low with no significant differences in expression between cell lines (Figure ​(Figure1).1). Among the seven sulfotransferases tested, only CHST11 expression levels trended well with the metastatic potential of cells, ranging from a low in MCF7, intermediate to high in MDA-MB-468 and high in MDA-MB-231 and MDA-MET cells (Figure ​(Figure1).1). The expression level of CHST11 was elevated with the increase in metastatic potential of cells. Such a trend was not observed with the expression levels of other genes examined. Therefore, the data may implicate the immediate product of CHST11 expression, CS-A, in the metastatic behavior of these cells.

The expression of the chondroitin sulfotransferase genes, in the breast cancer cells used. The expression of CHST3, CHST7, CHST11, CHST12, CHST13, CHST14, CHST15 was measured by qRT-PCR and normalized using18S. Data were analyzed by one-way ANOVA and...

Flow cytometry analysis of the binding of the anti-CS-A mAb 2H6, consistent with qRT-PCR data, indicates that the expression of CS-A was lower in the least aggressive MCF7 cell line and high in the most aggressive MDA-MB-231 and MDA-MET cell lines (Figure ​(Figure2A).2A). While MDA-MB-468 showed higher expression of CS-A than MCF7 cells, the CS-A expression in MDA-MB-468 was not different than its expression in MDA-MB-231 and MDA-MET. The lack of a difference in CS-A between these three cell lines could be due to the expression level of CHST15 that can turn the 4-sulfated product of CHST11 to CS-E. The expression of CHST15 was significantly lower in MDA-MB-468 than in MDA-MB-231 or MDA-MET (Figure ​(Figure1)1) making the conversion of some CS-A to CS-E much more likely in MDA-MB-231 and MDA-MET than in MDA-MB-468. Among the sulfotransferase genes examined, P-selectin binding to these cells correlated the best with CHST11 expression. We performed a correlation analysis of the gene expression levels and the mean fluorescence intensities of P-selectin binding among all cell lines studied and observed that only CHST11 (r = 0.85, P < 0.0001) showed a statistically significant correlation with P-selectin binding (Table ​(Table2).2). P-selectin reactivity with cell lines was comparable to anti-CSA 2H6 binding (Figure 2A, B). These data suggest that CHST11 (a chondroitin-4-sulfotransferase) expression in these cells is associated with the production of P-selectin ligands.

Correlation coefficients between P-selectin binding to cells and the expression of the sulfotransferases studied

Inhibition of CHST11 expression results in inhibition of CS-A production and P-selectin binding

Our data indicate that CHST11 is required for P-selectin binding. To confirm a role of 4-O sulfated structures in P-selectin binding, the expression of CHST11 in MDA-MB-231 cells was inhibited by siRNA. We observed that CHST11 mRNA levels, anti-CS-A binding and P-selectin binding were all significantly reduced upon treatment with the three siRNAs tested (Figures 3A, B). Transfection with siRNA # 31 (Table ​(Table1)1) showed the highest inhibitory effect on binding of anti-CS-A and recombinant P-selectin (Figure ​(Figure3B).3B). In three independently conducted experiments, transfection with siRNA #31 significantly reduced the mean fluorescence intensity for anti-CS-A (P ≤ 0.015) and P-selectin (P ≤ 0.001) binding, as compared with vehicle-treated cells.

Inhibition of CHST11 expression and P-selectin binding to MDA-MB-231 cells by CHST11 siRNA. MDA-MB-231 cells were treated with three different siRNAs for the CHST11 gene. RNA was harvested after 48 hours and gene expression was assayed at the mRNA level...

We repeated the CHST11 siRNA assay and did not observe any effect on the CSPG4 transcript or its surface expression as assayed by anti-CSPG4 mAb (Additional file 1). GAPDH siRNA was used as control in siRNA assays and reduced GAPDH mRNA by 75% in multiple assays (data not shown). Treatment of MDA-MB-231 cells with GAPDH siRNA did not inhibit CHST11 expression (data not shown). CHST11 siRNA sequences did not affect expression of GAPDH (data not shown). Therefore the expression of CS-A and binding of P-selectin to this cell line depends on the expression of the CHST11 gene.

CSPG4 expressed on aggressive breast cancer cells functions as a P-selectin ligand through its CS-GAGs

Because CS/DS-GAG expression and function depends on the composition of PGs expressed, studying the nature of the PG(s) involved in presentation of P-selectin-reactive CS/DS is important. Such studies should help us understand the functional consequences of CS/DS-GAG, PG and P-selectin interactions and provide data that may, in future studies, be used to manipulate the expression of the polysaccharide by targeting the core protein(s). Several membrane PGs, including SDC-1, SDC-4, NRP-1, and CSPG4 can potentially present GAG chains on the surface of tumor cells [53-55]. CSPG4 is the only cell surface PG that is exclusively decorated with CS-GAGs [41] and therefore, it may play a major role in forming cell surface CS-GAGs. We compared the expression of CSPG4 in the above described human breast cancer cell lines. The results of qRT-PCR indicate that the less aggressive epithelial-like cell lines MCF7 and MDA-MB-468 did not express CSPG4, while the gene was highly expressed in the highly aggressive mesenchymal-like cell lines MDA-MB-231 and MDA-MET (Figure ​(Figure4A).4A). Flow cytometry analysis further confirmed that the expression of CSPG4 was high in aggressive cell lines MDA-MB-231 and MDA-MET with almost no expression detected in the less aggressive cell lines MCF7 and MDA-MB-468 (Figure ​(Figure4B4B).

The expression of CSPG4 in aggressive breast cancer cell lines contributes to P-selectin binding. A) CSPG4 mRNA was measured by qRT-PCR and normalized to 18S values and log transformed. Means and standard deviations are shown. Comparisons were made by...

Because CSPG4 is abundant on aggressive cells, we hypothesized that it may function as a major core protein presenting CS-A and CS-related P-selectin ligands. We used CSPG4 siRNA to inhibit CSPG4 expression (Additional file 2). Inhibiting CSPG4 transcript in turn inhibited cell surface expression of the PG (Figure ​(Figure4C),4C), and that led to a drop in P-selectin (Figure ​(Figure4D)4D) and anti-CS-A binding (Figure ​(Figure4E).4E). We examined the transcript levels for CHST11 after transfection with CSPG4 siRNA (Additional file 2). Inhibition of expression of CSPG4 did not affect the expression of CHST11, indicating independence of expression of these two genes. This suggests that a decrease in CS-A after CSPG4 siRNA treatment (Figure ​(Figure4E)4E) is due to reduced expression of CSPG4 and not of CHST11. These data suggest that CSPG4 participates in forming P-selectin ligands on the surface of highly aggressive human breast cancer cells, but obviously it is not the only PG involved in CS-GAG presentation. Others have reported the expression of syndecans and NRP-1 in these breast cancer cell lines and it is known that these PGs can present CS-GAGs [36-38,54-56]. To confirm, we further examined the expression of SDC-1, SDC-4, NRP-1, and CSPG4 by qRT-PCR (Table ​(Table3).3). The expression of SDC-1 was lower in cells with highest metastatic potential and the expression of NRP-1, SDC-4 and CSPG4 was significantly higher in the most aggressive cells. The abundance of CS-A expression in MDA-MB-468 (a cell line with intermediate aggressiveness (Figure ​(Figure2A),2A), combined with the lack of CSPG4 expression in this cell line (Figure 4A, B), suggest that CS chains on this cell line are probably presented by other PGs (Table ​(Table33).

In order to confirm that P-selectin binds to CSPG4 we used CSPG4-transfected M14 melanoma cell line available in the lab. In prescreening of the M14 cell line, it appeared that this cell line expresses CHST11 with low binding of anti-CS-A 2H6 mAb and P-selectin, indicating that this cell line and its transfected version are excellent candidates for studying participation of CSPG4 and its CS GAGs in P-selectin binding. We observed that anti-CSPG4 225.28 mAb reacted with the transfected cells (M14-CSPG4) but not with mock-transfected M14 cells (Figure 5A, B, C). Anti-CS-A 2H6 mAb reacted with M14-CSPG4 but not with mock-transfected M14 cells (Figure ​(Figure5D).5D). P-selectin also reacted with M14-CSPG4 cells but not mock-transfected M14 cells, and treatment of M14-CSPG4 cells with chondroitinase ABC reduced the reactivity (Figure ​(Figure5E).5E). Pre-incubation of cells with 225.28 did not inhibit P-selectin binding (data not shown). These data suggest that CSPG4, via its CS chain, serves as a P-selectin ligand on the cell surface and that anti-CSPG4 225.28 mAb does not react with the GAG part of CSPG4. The data further suggest that overexpression of both CSPG4 and CHST11 genes in tumor cells may contribute to a superior metastatic potential.

Expression of CSPG4 leads to an increase in CS-A expression and P-selectin binding. A) Secondary Ab binding (control) to CSPG-4-transfected M14 (M14-CSPG4). Anti-CSPG4 (mAb 225.28) binding to M14-mock-transfected is minimal (B), while the binding is high...

CHST11 and CSPG4 are overexpressed in malignant tissues of breast cancer patients

In order to establish a translational relevance, we examined the expression of CSPG4 and CHST11 in specimens from breast cancer patients to compare the level of expression of these genes between normal and malignant tissues. Frozen sample-pair specimens from 15 breast cancer patients diagnosed with invasive ductal carcinoma were obtained from the UAMS tissue bank. In each sample pair, a tumor-containing sample was matched with tumor-free tissue from the same donor. We observed that these genes were overexpressed in tumor-containing tissues versus normal tissues (Figure ​(Figure6).6). CSPG4 and CHST11 expression showed an increase in tumor tissue over normal tissue in 10 out of 14 sample pairs and 8 out of 15 sample pairs, respectively. CSPG4 was elevated 3.2-fold (P < 0.02) in tumor tissue over normal tissue among 14 subjects, while CHST11 was elevated 1.8-fold (P = 0.034) in tumor over normal among 15 subjects (Figure ​(Figure6).6). Gene overexpression was detected in both ER-positive and ER-negative samples, but the majority of specimens with increased expression of CHST11 (seven out of eight), were HER2-neu-negative. These data suggest that despite the stromal expression of both CHST11 and CSPG4 genes the expression can be targeted specifically in aggressive tumors for therapeutic purposes. In this regard P-selectin binding to a relevant receptor on tumor cells may have profound impact on tumor cell dissemination and understanding the detail of such interaction may lead to development of novel anti-metastatic approaches.

Expression of the CSPG4 and the CHST11 genes was detected in breast tissue samples. mRNA expression was quantified by absolute quantification and the ratio of mRNA to 18S mRNA was calculated. The fold change in tumor sample compared to normal tissue sample...

CS-GAG removal inhibits tumor metastasis

We have previously suggested a role for CS/DS-GAGs in metastasis of the murine mammary cell line 4T1 [24]. To directly link CS/DS-GAGs to tumor metastasis, we examined whether removal of the cell surface CS/DS-GAGs affects metastasis of 4T1 cells in vivo. Here we demonstrate that removing CS/DS-GAGs by treating cells with chondroitinase ABC attenuated lung metastases in the 4T1 murine tumor model (Figure ​(Figure7).7). Chondroitinase treatment of cells prior to tail-vein injection significantly reduced lung metastases (P = 0.0002). The data indicate a significant role for tumor surface CS/DS-GAGs in establishing lung metastases in this breast cancer model and further support a likely role for P-selectin interaction with CS/DS-GAG in breast cancer metastasis.

Enzymatic removal of surface CS-GAGs reduced lung colonization of 4T1 cells. 4T1 cells were treated with chondroitinase ABC or buffer and injected into the tail vein of BALB/c mice (10 per group). Mice were sacrificed 25 days later and the number of metastases...

Discussion

Tumor cell dissemination by platelets leads to colonization of cancer cells to secondary organs resulting in poor prognosis and high mortality of cancer patients. P-selectin is present on activated platelets and endothelial cells while CS/DS-GAGs on the surface of breast cancer cells with high metastatic potential serve as P-selectin ligands [24]. The role of P-selectin in heterotypic adhesion is a critical component determining the efficiency of tumor cell dissemination [16,17]. The study of P-selectin-reactive molecules on tumor cells is crucial for the assessment of metastatic risk and the development of possible ways of dealing with metastatic disease. Such studies are needed to ultimately reveal the functional consequences of P-selectin/ligand interaction in tumor progression, making specific links between platelets and tumor metastasis.

Our results suggest the CHST11 gene as a major player in production of such P-selectin ligands. The results using CHST11 siRNA further suggest that among the chondroitin sulfotransferases tested, CHST11 expression has a rate limiting role in constructing both CS-A chains and P-selectin ligands on MDA-MB-231 cells. This data directly links expression of the CHST11 gene to P-selectin-reactive GAGs on this cell line and has significant implications for further functional studies. CS-A is an immediate product of CHST11 expression and is considered a precursor in forming CS-E units [57]. P-selectin has been shown to bind to CS-E [23]. We have also shown that exogenous CS-E inhibits P-selectin binding to cancer cells [24]. While we do not rule out participation of CS-E in P-selectin binding, our data do not support CS-E as the P-selectin reactive GAG unit on these cells. The combined high expression of these two genes may associate with P-selectin-reactive glycans and aggressiveness. This possibility should be investigated in future studies. However, the data indicate that the expression of the CHST11 gene in tumor cells is associated with synthesis of P-selectin ligands and a metastatic phenotype. Others have suggested a role for CS-A in tumor progression and metastasis in a melanoma model [46]. However, our data suggest that surface presentation of CS-A may be required but is not sufficient for a metastatic phenotype to occur. Besides its role in constructing CS-A, CHST11 also plays a role in chain elongation and production of more CS [57]. Chain elongation activity of CHST11 with a fine balance in the expression of other enzymes might be needed for constructing conformational epitopes. Thus, CHST11 activity may lead to larger CS polymers with multiple sequences embedded with distinct sulfation patterns resulted from activity of multiple sulfotransferases, leading to the production of conformational epitopes or highly concentrated sequences with specific reactivities. Thereby, the expression of CHST11 may correlate better with the tumor cells' aggressive phenotype than does the prevalence of any particular CS isomers.

Interestingly, our current results implicate CSPG4 in the presentation of CS moieties as P-selectin ligands. CSPG4 exclusively presents CS-GAGs, and the data described here suggest that these structures interact with P-selectin and, therefore, may contribute to distant metastasis of tumor cells. Our data indicate that P-selectin binds to CSPG4 through CS-GAGs and that CSPG4 is involved in P-selectin binding to CSPG4-expressing breast cancer cells. However, other PGs may also participate in P-selectin binding as expression of SDC-4 and NRP-1 is also higher in MDA-MB-231 and MDA-MET. Lack of expression of CSPG4 in MDA-MB-468 further suggests that anti-CS-A and P-selectin binding to these cells is probably due to expression of other PGs and not CSPG4. However, because of the role of CSPG4 in signaling and tumor phenotype, we speculate that its interaction with P-selectin may lead to an exclusive tumor cell activation and consequently survival in circulation. Therefore, concerted upregulation of CSPG4 and CHST11 may induce expression of a unique molecular entity that may increase the metastatic capabilities of tumor cells. More studies are needed to understand the consequences of P-selectin binding to CS-GAGs of multiple PGs and to reveal how and at what stage of the metastatic cascade the CS-GAGs and their carrier proteins contribute to metastasis.

We have shown glycan interactions with P-selectin and the significance of P-selectin binding in metastasis of a murine mammary cell line [24,52]. Our previous findings support the concept that CS chains promote survival in the circulation and tumor cell extravasation via P-selectin-mediated binding to platelets and endothelial cells. In the current study, the significance of the cell surface expression of CS-GAGs in a breast cancer model is established. The data demonstrate that enzymatic removal of the CS chains significantly attenuated formation of lung metastases in a highly metastatic mammary cell line. Others have shown that P-selectin ligands are critical components of heterotypic adhesion, determining the efficiency of tumor cell dissemination [16,17]. Sugahara's group demonstrated that highly sulfated CS-GAGs, in particular CS-E, are involved in metastasis of murine lung carcinoma and osteosarcoma cells [58,59]. However, our data suggest a role for 4-O sulfation of chondroitin in the metastatic phenotype. Moreover, the data suggest that the presence of CS/DS-GAGs may not be sufficient for a phenotype with high metastatic capacity to occur. The data emphasize a combination of the polysaccharide and a core protein as a pro-metastatic entity. Future studies are needed to understand the contribution of each PG in P-selectin mediated tumor cell behavior.

We further showed that the expression of CHST11 and CSPG4 is elevated in tumor tissues from breast cancer patients. Consistent with our data, CHST11 expression has been shown to be greater in human breast carcinoma compared to normal breast tissue [60] and in malignant plasma cells from myeloma patients compared to normal bone-marrow plasma cells [61].

The current research should lead to future studies of functional relationships between CS and tumor progression. Existing knowledge and further mechanistic studies might suggest CS-GAGs and their presenting PGs as targets for antimetastatic therapies. In support of work done in melanoma [62] and recent studies in breast cancer [39], the studies outlined here strongly suggest that CSPG4 can be an available target for immunotherapy of breast cancer. However, in order to efficiently block tumor cell dissemination by interrupting P-selectin/CS interaction, targeting any single PG does not seem enough as other PGs can probably compensate and support metastatic processes. In this regard, global targeting of specific CS isomers may be a particularly effective approach.

Breast cancer cell surface is decorated with CS-GAGs and due to tumor-specific expression patterns of chondroitin sulfotransferases and PGs, the composition and binding specificity of these polysaccharides differ from those of normal tissues. Therefore, these molecules and their interaction with P-selectin should be considered as viable targets for the development of novel therapeutic strategies.

Conclusions

This study demonstrates the significance of CS-GAGs in the lung colonization of an aggressive murine mammary cell line. The study reveals that CSPG4 can serve as a P-selectin ligand through its CS chain and that the expression of the CHST11 gene controls P-selectin reactive CS-GAGs formation. The data suggest that CS-GAGs, their biosynthetic pathway, or the core protein carrying them can be potential-targets for the development of therapeutic strategies for treatment of aggressive breast tumors. The knowledge and perspective gained from this line of research together with further mechanistic studies may pave the road to target CS-GAGs, their carrier PGs and their interaction with P-selectin as novel antimetastatic therapies.

Competing interests

BMK and TKE are named as inventors on an institutional patent application filled by UAMS that is related to the content of this manuscript. No financial or other support of any kind has resulted from this patent application. The other authors declare that they have no competing interests.

Authors' contributions

CAC participated in data interpretation, and was involved in drafting, critically reviewing and revising the manuscript. FJ carried out tissue culture, animal experiments, cell treatment and flow cytometry assays. AYB participated in the design of real-time PCR assays and helped draft the manuscript. BP carried out siRNA and real-time PCR assays. TG and AMKE carried out the additional gene expression analyses added to the revised manuscript. ERS performed statistical analyses and helped draft the manuscript. SF, TKE, and LJS participated in design of the study and helped draft the manuscript. BMK conceived of the study, designed experiments, coordinated the study and drafted the manuscript. All authors deserve the authorship right and they read and approved the final manuscript.

Supplemental Figure S2. Fold change in the expression of CHST11 and CSPG4 mRNA after transient transfection with CSPG4 siRNA. The expression of genes was measured 48 hours post transfection by qRT-PCR. Fold change is calculated based on the expression of genes in vehicle-treated cells. GAPDH message was used to normalize the data. Transfection with a scrambled siRNA was used as additional control. **, significantly different than expression in either cells only or cells transfected with scrambled siRNA at P < 0.01.

Acknowledgements

This study was supported in part by a pilot project grant through the UAMS Center for Clinical and Translational Research, Award Number 1UL1RR029884 from the National Center for Research Resources, and, in part, by a UAMS College of Medicine grant (both to BMK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank the UAMS Tissue Bank for human breast cancer tissues.